1 / 7

Rudra Investment Technical And Derivative Report(23rd April)

Sun Pharmaceutical Industries' one of the wholly owned subsidiaries<br>has increased its shareholding in Ranbaxy Malaysia, Malaysia, by way<br>of further purchase of 394,404 shares of face value of MYR 1.00 each<br>(equivalent to 4.93%) of Ranbaxy Malaysia. Ranbaxy Malaysia is a<br>subsidiary of the company, and the total shareholding of Sun<br>Pharmaceutical Industries, along with its wholly owned subsidiary is<br>90.74%, prior to this purchase of shares. the total holding of the<br>company along with its wholly owned subsidiary will increase from<br>90.74% to 95.67% in Ranbaxy Malaysia.

rakeshcplife
Download Presentation

Rudra Investment Technical And Derivative Report(23rd April)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Technical & Derivative Report 23TH APRIL 2018 www.rudrainvestment.com

  2. Daily Trading Bites NIFTY SNAPSHOT INDEX NIFTY 50 BANKNIFTY OPEN 10563 25111 HIGH 10597 25111 LOW 10531 24862 CLOSE 10595 25050 ADVANCE/DECLINE RATIO OPEN INTEREST AND VOLUME INDEX NIFTY INDEX NIFTY OI CURRENT 26879925 PREVIOUS 26850300 % CHANGE 1.01 ADVANCES 17 DECLINES 33 NIFTY VOLUME 106390 75007 1.57 BANKNIFTY OI 1884720 82527 1898240 73695 0.99 1.23 UNCHANGED 0 BANKNIFTY VOLUME www.rudrainvestment.com

  3. NIFTY GAINERS NIFTY LOSERS SYMBOL CMP % CHANGE SYMBOL CMP % CHANGE YESBANK 309.00 2.98 TCS 3414 6.98 ICICIBANK 282.50 2.45 TECHM 696.10 4.65 TATASTEEL 607.05 2.40 INFY 1179.65 4.13 SBIN 241.85 1.75 HCLTECH 1057.00 3.77 BAJFINANCE 1881.00 1.69 COALINDIA 291.35 2.88 www.rudrainvestment.com

  4. FII ACTIVITIES ( RS. IN CRORE) Market News: •VA Tech Wabag bags an order worth Rs. 253 crore by Bihar Urban Development Corporation (BUIDCO), under the prestigious Namami Gange scheme (National Mission for Clean Ganga NMCG). • •Vascon Engineers bags contract worth Rs 119 crore from Adhiraj Constructions, a Domestic Entity for the work of Civil and Structural Works (Residential Township) at Rohinjan Village, Taloja Node, Navi Mumbai amounting to Rs 119 crore. •Essel Propack has exercised call option to redeem the entire outstanding of 'Series B' Non-Convertible Debenture (NCDs) worth Rs 40 crore. FII GROSS PURCHASE GROSS SALES NET PURCHASE/ SALES Infrastructure 20-Apr-2018 19-Apr-2018 18-Apr-2018 5297.51 4838.37 4064.60 5318.53 5463.36 4980.31 21.02 624.99 915.71 DII ACTIVITIES ( RS. IN CRORE) DII GROSS PURCHASE GROSS SALES NET PURCHASE/ SALES 20-Apr-2018 4063.05 3952.04 111.01 19-Apr-2018 3371.41 2922.8 448.61 18-Apr-2018 3379.06 2509.36 869.70 www.rudrainvestment.com

  5. NIFTY WRAP CHART NIFTY Outlook Nifty settled down 1 points to 10564. Benchmark indices were flat on Friday even as minutes of the central bank’s policy panel meeting stoked expectations of an interest rate hike, with losses in financials and metals overshadowing gains in information technology stocks. The immediate resistance and support are 10700 and 10500 respectively. www.rudrainvestment.com

  6. Sun Pharma’s arm hikes stake in Ranbaxy Malaysia Sun Pharmaceutical Industries' one of the wholly owned subsidiaries has increased its shareholding in Ranbaxy Malaysia, Malaysia, by way of further purchase of 394,404 shares of face value of MYR 1.00 each (equivalent to 4.93%) of Ranbaxy Malaysia. Ranbaxy Malaysia is a subsidiary of the company, and the total shareholding of Sun Pharmaceutical Industries, along with its wholly owned subsidiary is 90.74%, prior to this purchase of shares. the total holding of the company along with its wholly owned subsidiary will increase from 90.74% to 95.67% in Ranbaxy Malaysia. www.rudrainvestment.com

  7. DISCLAIMER: Trading/investing in Stock Market involves considerable risk; you may lose part or all of the initial investment. It is not ideal for all types of investors. Past performance may not necessarily be repeated in the future. The views & tips provided is based on information & analysis which is believed to be accurate. This information is provided to enable you to make your own investment decisions and should not be construed as investment advice. Rudra Investment not offer any product/service with assured/guaranteed returns. The anticipatory moves mentioned are purely subject to technical studies and does not take into consideration sudden currency volatility and data events. The author, directors and/or employees of Rudra Investment cannot be held responsible for the accuracy of the tips. For more information and terms & condition kindly visit our website. All information offered at Rudra Investment is copyright protected and copying or redistribution of information, reports and news is strictly prohibited. Our visitors do acknowledge that warranty that is offered in connection with services and products described herein is offered completely by the advertiser or supplier of that product and not by Rudra Investment. We do not warrant that access to our site and relevant services would be error free or uninterrupted that defects gets corrected. We are not accountable for viruses, irregularities, damage to the computers that result from availing, accessing or downloading any information from our website. For More Info Visit Here:- http://rudrainvestment.com/

More Related